Clinical trials: Letrozole
Advanced Breast Cancer
Emulation of the MONALEESA-2 Trial Using Specialty Oncology Electronic Health Records Databases
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials.
- Trial name
- NCT07274709
- Testing
- Initiation of ribociclib, Initiation of letrozole
- Where
- United States
- Volunteers
- 2,495 people
- Sponsor
- Shirley Vichy Wang
PCOS (Polycystic Ovary Syndrome)
Letrozole and Cabergoline Versus Letrozole Alone in Ovulation Induction
Polycystic Ovarian Syndrome (PCOS) is the most common endocrine disorders in women of reproductive age. According to the World Health Organization (WHO) estimation revealed over 116 million women (3.4%) are affected by PCOS…
- Trial name
- NCT07168837
- Testing
- Letrozole tablets
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Al-Azhar University
Advanced Breast Cancer
A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer
GB491-005 is a multicenter, open-label, phase Ib Clinical Trial study to evaluate the safety, pharmacokinetic (PK), pharmacodynamic (PD) activity, and preliminary anti-tumor activity of GB491 in combination with Letrozole in…
- Trial name
- NCT05337657
- Testing
- GB491+Letrozole
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Genor Biopharma Co., Ltd.
Early Breast Cancer
Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer
This is a multicenter, open-label, single-arm, one-stage, phase II study to assess the efficacy of a chemotherapy-free pathological complete response (pCR)-guided strategy with trastuzumab and pertuzumab (given as a subcutaneous…
- Trial name
- PHERGAIN-2 (NCT04733118)
- Testing
- Trastuzumab and Pertuzumab (FDC SC) and T-DM1
- Where
- 41 sites in Bulgaria, Germany and 3 more
- Volunteers
- 393 people
- Sponsor
- MedSIR
Breast Cancer
Open Label Trial for Post-Menopausal Women With Newly Diagnosed Operable Breast Cancer
The purpose of this study is to determine pathological response to a maximum of 18 weeks of neoadjuvant therapy using a combination of letrozole and Bevacizumab in post-menopausal women with pathologically confirmed invasive…
- Trial name
- NCT00161291
- Testing
- Letrozole in combination with Bevacizumab
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Alabama at Birmingham
Metastatic Breast Cancer
Study of GnRH-A [Leuprorelin(Lorelin Depot] Plus Leterozole +/- Everolimus for Premenopausal Women With Metastatic Breast Cancer
The purpose of this study is to evaluate the efficacy of addition of everolimus to letrozole with LHRH agonist in premenopausal metastatic breast cancer patients who failed to tamoxifen treatment.
- Trial name
- LEO (NCT02344550)
- Testing
- Everolimus(afinitor), Letrozole, Leuprolide(Lorelin Depot)
- Where
- South Korea
- Volunteers
- 137 people
- Sponsor
- Asan Medical Center
Diminished Ovarian Reserve
SMART Protocol vs Antagonist Protocol in IVF
This retrospective study aims to assess the effect of adding letrozole in patients who have previously undergone an IVF cycle with either an antagonist or short protocol, with patients who have undergone a second cycle of IVF…
- Trial name
- NCT05677828
- Where
- Canada
- Volunteers
- 426 people
- Sponsor
- Clinique Ovo
Breast Cancer
Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.
This was a randomized, double-blind, placebo-controlled study conducted in Chinese women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer, plus an open-label…
- Trial name
- NCT03671330
- Testing
- Ribociclib, NSAI: Letrozole or Anastrazole, Goserelin
- Where
- 24 sites in China
- Volunteers
- 327 people
- Sponsor
- Novartis Pharmaceuticals
Estrogen Receptor Positive, Postmenopausal
Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer
This phase II trial studies how well ribociclib and letrozole work in treating patients with estrogen receptor (ER) positive ovarian, fallopian tube, primary peritoneal, or endometrial cancer that has returned (come back) after a…
- Conditions
- Estrogen Receptor Positive, Postmenopausal, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
- Trial name
- NCT02657928
- Testing
- Laboratory Biomarker Analysis, Letrozole, Ribociclib
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Mayo Clinic
Breast Cancer
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Anastrozole vs Exemestane/Letrozole
This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the…
- Trial name
- NCT05635357
- Testing
- Anastrozole, Exemestane/Letrozole
- Where
- United States
- Volunteers
- 16,989 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Metastatic Breast Cancer
Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer
Letrozole is an aromatase inhibitor that is approved in the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer.
- Trial name
- NCT00634634
- Testing
- Sorafenib, Letrozole
- Where
- 4 sites in United States
- Volunteers
- 52 people
- Sponsor
- Rutgers, The State University of New Jersey
Early Breast Cancer
Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients
Phase II, randomized, open-label, international, multicenter study to compare efficacy of standard chemotherapy vs. letrozole plus abemaciclib as neoadjuvant therapy in HR-positive/HER2-negative high/intermediate risk breast…
- Trial name
- CARABELA (NCT04293393)
- Testing
- Doxorubicin, Cyclophosphamide, Taxane
- Where
- 28 sites in Spain
- Volunteers
- 200 people
- Sponsor
- Spanish Breast Cancer Research Group
Breast Cancer
Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib
The purpose of this study is to better understand how the immune system plays a role in fighting breast cancer and specifically research if the immune system response against breast cancer can be improved with endocrine therapy…
- Trial name
- NCT04614194
- Testing
- Letrozole, Abemaciclib
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of Texas Southwestern Medical Center
Breast Cancer Female, Healthy Female
Breast Cancer & Antiestrogenic Therapy & Brain
The study aims to investigate the effect of anti-estrogenic therapy in breast cancer patients on neural reward processing, psychosexual health, and quality of life, in reproductive vs. menopausal women.
- Conditions
- Breast Cancer Female, Healthy Female, Menopause, Anti-estrogenic Therapy
- Trial name
- NCT06346457
- Testing
- Tamoxifen, Letrozole, Letrozole + GnRH
- Where
- Germany
- Volunteers
- 180 people
- Sponsor
- International Research Training Group 2804
Breast Cancer, Early Breast Cancer
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease…
- Trial name
- CAMBRIA-2 (NCT05952557)
- Testing
- Camizestrant, Tamoxifen, Anastrozole
- Where
- 661 sites in United States, Argentina and 42 more
- Volunteers
- 5,511 people
- Sponsor
- AstraZeneca
Embryo Transfer, Irregular Menstruation
Letrozole-stimulated Cycle Strategy Versus Artificial Cycle Strategy (LETSACT)
The goal of this randomized clinical trial is to evaluate the effectiveness of the letrozole-stimulated cycle strategy versus the artificial cycle strategy for endometrial preparation in women with irregular menstrual cycles…
- Conditions
- Embryo Transfer, Irregular Menstruation, Letrozole, Hormone Replacement Therapy
- Trial name
- NCT06372119
- Testing
- Letrozole-stimulated cycle strategy, Artificial cycle strategy
- Where
- 2 sites in Vietnam
- Volunteers
- 790 people, healthy volunteers welcome
- Sponsor
- Mỹ Đức Hospital
Breast Cancer, Chemotherapy
Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer
Breast cancer is the most common female malignancy in the world, and the leading cause of cancer-associated mortalities among women.
- Conditions
- Breast Cancer, Chemotherapy, Endocrine Breast Diseases
- Trial name
- NCT03373708
- Testing
- Epirubicin, Cyclophosphamide, Docetaxel
- Volunteers
- 200 people
- Sponsor
- Zhiyong Yu
Breast Cancer Brain Metastases
Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.
This study evaluated the safety and efficacy of SPH4336 in combination with endocrine therapy in breast cancer Patients with brain metastases.
- Trial name
- NCT05872347
- Testing
- SPH4336 Tablets
- Where
- 25 sites in China
- Volunteers
- 52 people
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Breast Cancer, Osteoporosis
Zoledronate in Treating Osteopenia or Osteoporosis in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage IIIA Primary Breast Cancer
RATIONALE: Zoledronate may reduce bone loss in patients receiving letrozole for breast cancer. PURPOSE: This clinical trial is studying how well zoledronate works in treating osteopenia or osteoporosis in postmenopausal women…
- Trial name
- NCT00436917
- Testing
- zoledronic acid, Letrozole as adjuvant therapy
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Mayo Clinic
Breast Cancer
Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients
Men and post- or induced menopausal women with ER[+] and/or PgR[+], HER2[- ] advanced BC, with centrally-confirmed PI3KCAMut who progressed to an aromatase inhibitor (AI) regimen.
- Trial name
- METALLICA (NCT04300790)
- Testing
- Alpelisib, Metformin, Fulvestrant
- Where
- 19 sites in Spain
- Volunteers
- 69 people
- Sponsor
- MedSIR